Tang Capital Management LENZ Position
Active7-Fund ConvergenceTang Capital Management trimmed their position in LENZ Therapeutics, Inc. (LENZ) in Q4 2025, holding $13.8M worth of shares across 865,169 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
LENZ is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 52.7% of float with 13.3 days to cover, indicating significant bearish positioning against Tang Capital's long thesis.
3 insider purchases totaling $366K have been filed in the last 90 days, providing an additional conviction signal.
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Full company profile →Short Interest
52.7%
13.3 days to cover
Insider Buys (90d)
3
$366K total
Tang Capital Management LENZ Position History
Frequently Asked Questions
Does Tang Capital Management own LENZ?
Yes. As of Q4 2025, Tang Capital Management holds 865,169 shares of LENZ Therapeutics, Inc. (LENZ) valued at $13.8M. This data comes from their SEC 13F filing.
How many hedge funds own LENZ?
7 specialist biotech hedge funds currently hold LENZ, including RA Capital Management, RTW Investments, EcoR1 Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy LENZ?
Tang Capital Management's position in LENZ was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's LENZ position increasing or decreasing?
Tang Capital Management trimmed their LENZ position in the most recent quarter, reducing by 32,447 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LENZCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →